Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Issue 2 (5th January 2017)

• Record Type: Journal Article
• Authors: Young, Barnaby; Zhao, Xiahong; Cook, Alex R.; Parry, Christopher M.; Wilder-Smith, Annelies; I-Cheng, Mark Chen
• Is Part Of: Vaccine. Volume 35:Issue 2(2017)
• Page Start: 212
• Page End: 221
• Publication Date: 2017-01-05
• Subjects: Seasonal -- Influenza -- Vaccine -- Seroprotection -- Tropics -- Elderly; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2016.11.013
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Introduction: The influenza vaccine is less immunogenic in older than younger adults, and the duration of protection is unclear. Determining if protection persists beyond a typical seasonal epidemic is important for climates where influenza virus activity is year-round. Methods: A systematic review protocol was developed and registered with PROSPERO [CRD42015023847]. Electronic databases were searched systematically for studies reporting haemagglutination-inhibition (HI) titres 180–360 days following vaccination with inactivated trivalent seasonal influenza vaccine, in adults aged ⩾65 years. Geometric mean titre (GMT) and seroprotection (HI titre ⩾1:40) at each time point was extracted. A Bayesian model was developed of titre trajectories from pre-vaccination to Day 360. In the meta-analysis, studies were aggregated using a random-effects model to compare pre-vaccination with post-vaccination HI titres at Day 21–42 ('seroconversion'), Day 180 and Day 360. Potential sources of bias were systematically assessed, and heterogeneity explored. Results: 2864 articles were identified in the literature search, of which nineteen met study inclusion/exclusion criteria. Sixteen studies contained analysable data from 2565 subjects. In the Bayesian model, the proportion of subjects seroprotected increased from 41–51% pre-vaccination to 75–78% at seroconversion. Seroprotection subsequently fell below 60% for all serotypes by Day 360: A/H1 42% (95% CI 38–46), A/H3 59% (54–63), B 47% (42–52). The Bayesian model of GMT trajectories revealed a similar pattern. By Day 360, titres were similar to pre-vaccination levels. In the meta-analysis, no significant difference in proportion of subjects seroprotected, 0 (−0.11, 0.11) or in log2 GMT 0.30 (−0.02, 0.63) was identified by Day 360 compared with pre-vaccination. The quality of this evidence was limited to moderate on account of significant participant dropout. Conclusions: The review found consistent evidence that HI antibody responses following influenza vaccination do not reliably persist year-round in older adults. Alternative vaccination strategies could provide clinical benefits in regions where year-round protection is important.